51 withdrawn. 51 Phase 2, 14 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 51 | Withdrawn 51 |
| Phase 1 | 14 | Withdrawn 14 |
Follow Leukemia, B-Cell: new trials by email Literature Review of Leukemia, B-Cell trials Research Report on Leukemia, B-Cell
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate the Sequencing Strategy of Pirtobrutinib After Disease Progression on First-line Acalabrutinib Treatment for Adult Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Pirtobrutinib, Acalabrutinib - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Withdrawn | AstraZeneca | 2025-06-30 | 2025-06-05 | |
| Passive Antibodies Against COVID-19 With EVUSHELD in Vaccine Non-responsive CLL EVUSHELD - Chronic Lymphocytic Leukemia, COVID-19 | Phase 2 | Withdrawn | Sunnybrook Health Sciences Centre | 2023-10-01 | 2024-04-04 | |
| Anti-CD19 Universal CAR-NK Cells Therapy Combined With HSCT for B Cell Hematologic Malignancies anti-CD19 UCAR-NK cells - B-cell Lymphoma, B-cell Leukemia | Phase 1 / Phase 2 | Withdrawn | Kunming Hope of Health Hospital | 2022-10-01 | 2022-11-30 | |
| CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies CliniMACS, Bone Marrow Transplant, Hyperfractionated Total Body Irradiation - Hematologic Diseases, Hematologic Malignancy | Phase 2 | Withdrawn | Baptist Health South Florida | 2022-09-01 | 2022-09-27 | |
| Early Intervention With Acalabrutinib in Patients With High Risk CLL Acalabrutinib - Chronic Lymphocytic Leukemia, CLL/SLL | Phase 2 | Withdrawn | Weill Medical College of Cornell University | 2022-05-01 | 2022-04-05 | |
| Copanlisib Plus Ibrutinib or Acalabrutinib in R/R CLL Ibrutinib, Copanlisib, Acalabrutinib - Chronic Lymphocytic Leukemia (CLL) | Phase 2 | Withdrawn | Inhye Ahn | 2021-02-18 | 2025-05-22 | |
| Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19) Ibrutinib, Quality-of-Life Assessment - Asymptomatic COVID-19 Infection Laboratory-Confirmed, B-Cell Neoplasm | Phase 2 | Withdrawn | Academic and Community Cancer Research United | 2020-11-23 | 2022-08-03 | |
| Ibrutinib and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia After Ibrutinib Resistance Ibrutinib, Venetoclax - Chronic Lymphocytic Leukemia, Loss of Chromosome 17p | Phase 2 | Withdrawn | Kerry Rogers | 2020-03-11 | 2021-11-05 | |
| Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma Autologous CD19/CD22 Chimeric Antigen Receptor T-cells, Cyclophosphamide, Fludarabine - CD19 Positive, CD22 Positive | Phase 1 / Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2019-05-15 | 2023-08-21 | |
| Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications in Patients With Blood Cancer Undergoing Donor Stem Cell Transplant Multi-antigen CMV-Modified Vaccinia Ankara Vaccine, Laboratory Biomarker Analysis, Placebo - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia in Remission | Phase 2 | Withdrawn | City of Hope Medical Center | 2018-12-01 | 2018-11-21 | |
| Phase 2 Study of Duvelisib in Previously Treated Patients With Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma Duvelisib - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Withdrawn | SecuraBio | 2018-02-12 | 2023-02-28 | |
| Lenalidomide and Obinutuzumab for Previously Untreated CLL Lenalidomide, Obinutuzumab - Chronic Lymphocytic Leukemia | Phase 2 | Withdrawn | University of California, San Diego | 2018-02-01 | 2018-02-23 | |
| Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell Malignancies 4SCAR19/22 T cells, Interleukin-2 - B-Cell Leukemia, B-Cell Lymphoma | Phase 1 / Phase 2 | Withdrawn | Zhujiang Hospital | 2017-12-30 | 2024-03-18 | |
| Evaluation of the Immune Restoration Potential Of Lenalidomide Lenalidomide - Chronic Lymphocytic Leukemia (CLL) | Phase 2 | Withdrawn | University of California, San Diego | 2017-02-01 | 2017-04-28 | |
| Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Pacritinib, Ibrutinib - Chronic Lymphocytic Leukemia, Lymphoma, Small Lymphocytic | Phase 1 / Phase 2 | Withdrawn | University of Michigan Rogel Cancer Center | 2016-10-01 | 2017-09-06 | |
| Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma rituximab, lenalidomide, romidepsin - B-cell Adult Acute Lymphoblastic Leukemia, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Phase 1 / Phase 2 | Withdrawn | Mayo Clinic | 2016-10-01 | 2016-08-11 | |
| Treg Cells for AGVHD in Non-myeloablative UCB Transplant T Regulatory cells, Fludarabine, Cyclophosphamide - Hematologic Malignancies | Phase 2 | Withdrawn | Masonic Cancer Center, University of Minnesota | 2016-06-01 | 2017-12-02 | |
| Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant Ibrutinib, Idelalisib - Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia | Phase 2 | Withdrawn | Fred Hutchinson Cancer Center | 2016-03-01 | 2017-09-27 | |
| Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Brentuximab, Bendamustine, Rituximab - Diffuse Large B Cell Lymphoma, Mediastinal Large B-cell Lymphoma | Phase 2 | Withdrawn | University of Arizona | 2015-12-16 | 2017-05-19 | |
| Urelumab (CD137 mAb) With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients Rituximab, Urelumab - Leukemia | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2015-07-01 | 2016-12-06 |
Showing 20 of 51. Sign in to see all of them.
Leukemia, Lymphocytic, Chronic, B-Cell (48) · Leukemia (16) · Lymphoma, B-Cell, Marginal Zone (15) · Lymphoma, Non-Hodgkin (14) · Lymphoma, Follicular (13) · Lymphoma, Mantle-Cell (13) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (12) · Burkitt Lymphoma (11) · Lymphoma (11) · Lymphoma, Large B-Cell, Diffuse (9) · Leukemia, Myeloid, Acute (8) · Waldenstrom Macroglobulinemia (8) · Lymphoma, Large-Cell, Immunoblastic (7) · Myelodysplastic Syndromes (7) · Myeloproliferative Disorders (7)
Hemic and Lymphatic Diseases (51) · Immune System Diseases (51) · Immunoproliferative Disorders (51) · Leukemia, Lymphoid (51) · Lymphatic Diseases (51) · Neoplasms by Histologic Type (51) · Hematologic Diseases (50) · Lymphoproliferative Disorders (49) · Neoplasms (49) · Chronic Disease (48) · Disease Attributes (48) · Pathologic Processes (48) · Pathological Conditions, Signs and Symptoms (48) · Leukemia (35)
Rituximab (11) · Cyclophosphamide (8) · Lenalidomide (6) · fludarabine phosphate (6) · Bendamustine Hydrochloride (5) · Peripheral Blood Stem Cell Transplantation (5) · ibrutinib (5) · Whole-Body Irradiation (4) · fludarabine (4) · Cyclosporine (3) · Methotrexate (3) · Mycophenolic Acid (3) · Radiotherapy (3) · acalabrutinib (3) · Busulfan (2)
M.D. Anderson Cancer Center (5) · Fred Hutchinson Cancer Center (3) · Hoag Memorial Hospital Presbyterian (3) · Masonic Cancer Center, University of Minnesota (3) · University of California, San Diego (2) · Abbott (1) · Academic and Community Cancer Research United (1) · Alliance for Clinical Trials in Oncology (1) · AstraZeneca (1) · Baptist Health South Florida (1) · CABYC (1) · City of Hope Medical Center (1) · Cylene Pharmaceuticals (1) · Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium (1) · Gilead Sciences (1)
United States (26) · China (2) · Canada (1) · Spain (1)
Robert O. Dillman, MD, FACP (3) · Claudio Brunstein, MD, PhD (2) · Michael Choi, MD (2) · Amar Safdar, MD (1) · Asher Chanan-Khan (1) · Daniel J. Weisdorf, MD (1) · Daniel O. Persky, MD (1) · Darren Sigal, MD (1) · Deborah A. Thomas, MD (1) · Elizabeth Maher, MD, PhD (1) · Francesc Bosch, MD, PhD (1) · Grzegorz Nowakowski (1) · Guenther Koehne, MD (1) · H. Joachim Deeg, MD (1) · Hector A Preti, M.D. (1)
PMID 18003886, PMID 20408846, PMID 24443277
P30CA015083 (2), P30CA015704 (2), P01CA018029 (1), P01CA065493 (1), P30CA006973 (1), P30CA016056 (1), P30CA016672 (1), P30CA036727 (1), P30CA072720 (1), U10CA032102 (1)